Corpus Intelligence IC Memo — SPECIALTY HOSPITAL OF WASHINGTON 2026-04-26 08:01 UTC
IC Memo — SPECIALTY HOSPITAL OF WASHINGTON
Investment Committee Memorandum | DC | 60 beds | Grade C | EBITDA uplift $4.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SPECIALTY HOSPITAL OF WASHINGTON

CCN 092002 | DC, DC | 60 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SPECIALTY HOSPITAL OF WASHINGTON is a 60-bed suburban community hospital in DC, DC with $62.3M in net patient revenue and a 13.3% operating margin. The hospital serves a payer mix of 55.4% Medicare, 7.8% Medicaid, and 36.8% commercial.

Thesis: Turnaround. Our ML models identify $4.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 13.3% to 20.7% (+736bps).

Net Revenue HCRIS$62.3M
Current EBITDA COMPUTED$8.3M
Operating Margin COMPUTED13.3%
Occupancy HCRIS68.4%
Revenue / Bed COMPUTED$1.0M
Net-to-Gross HCRIS67.4%
Distress Probability ML50.2%

2. Market Context & Competitive Position

12
DC Hospitals
-2.9%
State Median Margin
2149
Comparable Hospitals

DC has 12 Medicare-certified hospitals with a median operating margin of -2.9%. The target's margin of 13.3% places it above the state median. Among 2149 size-comparable peers (30-120 beds), the median margin is -3.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (30-120), prioritizing same-state peers. 2149 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SPECIALTY HOSPITAL OF WASHINGT (Target)DC60$62.3M13.3%
DANA-FARBER CANCER INSTITUTEMA30$1.88B-35.1%
MIDWESTERN REGIONAL MEDICAL CEIL73$1.38B80.5%
SMDC MEDICAL CENTERMN118$519.2M-7.1%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
WENTWORTH DOUGLASS HOSPITALNH118$500.9M10.7%
MCHS - SOUTHWEST MINNESOTA REGMN118$473.6M-9.8%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
THE HEART HOSPITAL BAYLOR PLANTX109$464.6M25.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.3M+210bp18mo
Cost to Collect4.5%2.5%$1.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$758K+122bp9mo
Clean Claim Rate88.0%96.0%$40K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.3M
Cost to Collect
$1.2M
Denial Rate Reduction
$1.2M
A/R Days Reduction
$758K
Clean Claim Rate
$40K
Total EBITDA Uplift$4.6M
Current EBITDA$8.3M
+ RCM Uplift+$4.6M
Pro Forma EBITDA$12.9M
Current Margin13.3%
Pro Forma Margin20.7%
WC Released (1x)$2.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$12.7M$100.5M7.88x51.1%
Base (11x exit)10.0x11.0x$12.7M$114.7M9.00x55.2%
Bull Case9.0x11.0x$11.5M$134.0M11.68x63.5%
Bull (12x exit)9.0x12.0x$11.5M$149.5M13.03x67.1%
Bear Case11.0x10.0x$14.0M$73.4M5.24x39.3%
Bear (11x exit)11.0x11.0x$14.0M$85.3M6.09x43.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumHeavy Medicare dependenceMedicare comprises 55.4% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement
HighElevated distress probabilityModel estimates 50.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 2149 hospitals with 30-120 beds
  • Same-state prioritization (n=2)
  • Comp margins: P25=-16.3% / P50=-3.0% / P75=9.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.